VBIV
- VBI Vaccines Inc.
()
Overview
Company Summary
VBI Vaccines Inc. (VBIV) is a biopharmaceutical company focused on the development and commercialization of innovative vaccines for the prevention and treatment of infectious diseases. The company utilizes its proprietary enveloped virus-like particle (VLP) technology platform to design and produce vaccines that mimic the natural structure of viruses, enhancing their effectiveness.
VBI Vaccines is involved in various stages of vaccine development, including discovery, preclinical testing, clinical trials, and regulatory approval. The company aims to address unmet medical needs by targeting diseases with limited or no approved vaccines available.
One of VBI Vaccines' primary areas of focus is the prevention and treatment of hepatitis B virus (HBV) infections. They have developed a novel hepatitis B vaccine, called Sci-B-Vac, which is designed to provide a robust immune response compared to traditional vaccines. Sci-B-Vac has been shown to be effective in phase III clinical trials and has been approved for use in several countries.
In addition to HBV, VBI Vaccines is also developing vaccines for other infectious diseases such as cytomegalovirus (CMV) and glioblastoma. The company's CMV vaccine candidates aim to prevent CMV infection in pregnant women, potentially reducing the risk of birth defects. Their glioblastoma vaccine candidate is designed to stimulate the immune system to recognize and target cancerous cells in brain tumors.
VBI Vaccines collaborates with other pharmaceutical companies, research institutions, and government organizations to advance their vaccine candidates. By leveraging their proprietary technology, the company strives to develop safe and effective vaccines that can improve public health outcomes globally.
Overall, VBI Vaccines Inc. is committed to utilizing innovative technology and scientific expertise to develop vaccines for infectious diseases with a focus on unmet medical needs, such as HBV, CMV, and glioblastoma.